Johnson & Johnson (Pty) Ltd announced today it plans to split into two companies – separating its consumer health business, which is expected to generate $15bn in 2021 revenues, from its pharmaceutical and medical device businesses, which are expected to generate about $77bn in full-year revenues.
“For the new Johnson & Johnson, this planned separation underscores our focus on delivering industry-leading biopharmaceutical and medical device innovation...